Добавил:
ivanov666
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Хронический кардиоренальный синдром
.pdf
70. Butler J. Update of aldosterone antagonists use in heart failure
with reduced le ventricular ejection fraction heart failure
society of America guidelines committee / J. Butler // J Card
Fail. – 2012. – Vol. 18, N. 4. – P. 265–281.
71. Campbell R.C. Association of chronic kidney disease with
outcomes in chronic heart failure / R.C. Campbell // Nephrol
Dial Transplant. – 2009. – Vol. 24, N. 1. – P. 186–193.
72. Campean V. Atherosclerosis and vascular calcication in
chronic renal failure / V. Campean // Kidney Blood Press
Res. – 2005. – Vol. 28, N. 5. – P. 280–289.
73. Campese V.M. HMG–CoA reductase inhibitors and renal
function / V.M. Campese, J. Park // J Am Soc Nephrol. –
2007. – Vol. 2, N. 6. – P. 1100–1103.
74. Castagno D. Improved survival with bisoprolol in patients
with heart failure and renal impairment: an analysis of the
cardiac insuciency bisoprolol study II (CIBIS–II) trial /
D. Castagno // Eur J Heart Fail. – 2010. – Vol. 12, N. 6. –
P. 607–617.
75. Cerda J. Fluid overload in critically ill patients with acute
kidney injury / J. Cerda, G. Sheinfeld, C. Ronco // Blood
Purif. – 2010. – Vol. 29, N. 4. – P. 331–338.
76. Chaney E. Pathophysiology of uid retention in heart failure
/ E. Chaney, A. Shaw // Contrib Nephrol. – 2010. – Vol. 164,
N. 1. – P. 46–53.
77. Charpentier J. Brain natriuretic peptide: a marker of
myocardial dysfunction and prognosis during severe sepsis
/ J. Charpentier // Crit Care Med. – 2004. – Vol. 32, N. 3. –
P. 660–665.
78. Chrysant S.G. e treatment of cardiovascular disease
continuum: focus on prevention and RAS blockade / S.G.
Chrysant, G.S. Chrysant, M. Shiraz // Curr Clin Pharmacol. –
2010. – Vol. 5, N. 2. – P. 89–95.
79. Chuasuwan A. Cardio–renal syndrome type 3: epidemiology,
pathophysiology and treatment / A. Chuasuwan, J.A. Kellum
// Semin Nephrol. – 2012. – Vol. 32, N. 1. – P. 31–39.
211
80. Cockro D.W. Prediction of creatinine clearance from serum
creatinine / D.W. Cockro, M.H. Gault // Nephron. – 1976. –
Vol. 16, N.1. – P. 31–41.
81. Cohen N. Renal dysfunction in congestive heart failure,
pathophysiological and prognostic signicance / N. Cohen //
Clin Nephrol. – 2004. – Vol. 61, N. 3. – P. 177–184.
82. Cohen–Solal A. Ecacy and safety of nebivolol in elderly
heart failure patients with impaired renal function: insights
from SENIORS trial / A. Cohen–Solal // Eur J Heart Fail. –
2009. – Vol. 11, N. 9. – P. 872–880.
83. Colombo P.C. Activation of endothelial cells in conduit veins
of dogs with heart failure and veins of normal dogs aer
vascular stretch by active volume loading / P.C. Colombo // J.
Card. Fail. – 2009. – Vol. 15, N. 5. – P. 457–463.
84. Cosin J. Torasemide in chronic heart failure / J. Cosin, I. Diez
// Eur J Heart Fail. – 2002. – Vol. 4, N. 4. – P. 507–513.
85. Covic A. Vascular calcication in chronic kidney disease /
A. Covic // Clin Sci (Lond). – 2010. – Vol. 119, N. 3. – P. 111–121.
86. Damman K. Increased central venous pressure is
associated with impaired renal function and mortality in
a broad spectrum of patients with cardiovascular disease /
K. Damman // J Am Coll Cardiol. – 2009a. – Vol. 57, N. 7. –
P. 582–588.
87. Damman K. Both in–and outhospital worsening of renal
function predict outcome in patients with heart failure: results
from Coordinating Study Evaluating Outcome of Advising
and Consulting in Heart Failure (COACH) / K. Damman //
Eur J Heart Fail. – 2009b. – Vol. 11, N. 9. – P. 847–854.
88. Damman K. Congestion in chronic systolic heart failure
is related to renal dysfunction and increased mortality /
K. Damman // Eur J Heart Fail. – 2010. – Vol. 12, N. 9. –
P. 977–982.
89. Damman K. Tubular damage in chronic systolic heart
failure is associated with reduced survival independent of
glomerular ltration rate / K. Damman // Heart. – 2010. –
Vol. 96, N. 16. – P. 2705–2712.
212
90. Damman K. Volume status and diuretic therapy in systolic
heart failure and detection of early abnormalities in renal and
tubular function / K. Damman // J Am Coll Cardiol. – 2011. –
Vol. 57, N. 22. – P. 2233–2241.
91. Damman K. Clinical outcome of renal tubular damage in
chronic heart failure / K. Damman // Eur Heart J. – 2011. –
Vol. 32, N. 21. – P. 1987–1996.
92. Deo S.H. Statin therapy lowers muscle sympathetic nervous
activity and oxidative stress in patients with heart failure /
S.H. Deo // Am J Physiol Heart. – 2012. – Vol. 303, N. 3. –
P. H377–H385.
93. Despas F. Excessive sympathetic activation in heart failure
with chronic renal failure: role of chemoreex activation /
F. Despas // J Hypertes. – 2009. – Vol. 27, N. 9. – P. 1849–1854.
94. Dessai A. Impact of erythropoiesis–stimulating agents on
morbidity and mortality in patients with heart failure: an
update, post–TREAT meta–analysis / A. Dessai // Eur J Heart
Fail. – 2010. – Vol. 12, N. 9. – P. 936–942.
95. DiBona G.F. Eect of metoprolol administration on renal
sodium handling in experimental congestive heart failure /
G.F. DiBona, I.I. Sawin // Circulation. – 1999. – Vol. 100, N. 1. –
P. 82–86.
96. Ding M. Loss of the tumor suppressor Vhlh leads
to upregulation 0f Cxcr4 and rapidly progressive
glomerulonephritis in mice / M. Ding // Nat Med. – 2006. –
Vol. 12, N. 9. – P. 1081–1087.
97. Dini F.L. Right ventricular dysfunction is associated with
chronic kidney disease and predict survival in patients with
chronic systolic heart failure / F.L. Dini // Eur J Heart Fail. –
2012. – Vol. 14, N. 3. – P. 287–294.
98. DiNicolantonio J.J. Should torasemide be the loop diuretic
chouse in systolic heart failure // Future cardiol. – 2012. –
Vol. 8, N. 5. – P. 707–728.
99. Dinnen S.F. e association of microalbuminuria and
mortality in non–insulin–dependent diabetes mellitus:
213
A systematic overview of literature / S.F. Dinnen // Arch
Intern Med. – 1997. – Vol. 157, N. 13. – P. 1413–1418.
100. Doty J.M. Eect of increased renal venous pressure on renal
function / J.M. Doty ] // J Trauma. – 1999. – Vol. 47, N. 6. –
P. 1000–1003.
101. Drummond W. Antihypertensive ecacy of the oral direct renin
inhibitor aliskiren as add–on therapy in patients not responding
to amlodipine monotherapy / W. Drummond // Clin Hypertens
(Greenwich). – 2007. – Vol. 9, N. 10. – P. 742–750.
102. Duda M. ω–3 polyunsaturated fatty acid supplementation
for the treatment of heart failure: mechanisms and clinical
potential / M. Duda, K.M. O’Shea, W.C. Stanley // Cardiovasc
Res. – 2009. – Vol. 84, N. 1. – P. 33–41.
103. Dummaine R.L. Renal function, atherothrombosis extent
and out comes in high risk patients / R.L. Dummaine // Am
Heart J. 2009. – Vol. 158, N. 1. – P. 141–148.
104. Dummer C.D. Chronic renal disease, inammation and
atherosclerosis: new concepts about an old problems /
C. D. Dummer // Rev Assoc Med Bras. – 2007. – Vol. 53, N. 5. –
P. 446–450.
105. Eckardt K.U. Le ventricular geometry predicts cardiovascular
outcomes associated with anemia in CKD / K.U. Erckardt //
J Am Soc Nephrol. – 2009. – Vol. 20, N. 12. – P. 2651–2660.
106. Edwards N.S. Aortic distensibility and arterial–ventricular
coupling in early chronic kidney disease / N.S. Edwards,
C.J. Ferro, J.N. Townend // Heart. – 2008. – Vol. 94, N. 8. –
P. 1038–1043.
107. Emans M.E. Neutrophil gelatinase–associated lipocalin
(NGAL) in chronic cardiorenal failure is correlated with
endogenous erythropoietin levels and decrease to low–dose
erythropoietin treatment / M.E. Emans // Kidney Blood Press
Res . – 2012. – Vol. 36, N. 1. – P. 344–354.
108. ESC Guidelines for diagnosis and treatment of acute and
chronic heart failure 2008 // Eur Heart J. – 2008. – Vol. 29,
N. 19. – P. 2388–2442.
214
109. ESC Guidelines for diagnosis and treatment of acute and
chronic heart failure 2012 // Eur Heart J. – 2012. – Vol. 33, N.
14. – P. 1787–1847.
110. Evans R.G. Intrarenal oxygenation: unique challenges and
the biophysical basis of homeostasis / R.G. Evans // Am J
Physiol Renal. – 2008. – Vol. 295, N. 5. – P. F1259–F1270.
111. Evans R.G. Stability of tissue pO2 in the face of altered
perfusion: a phenomenon specic to the renal cortex
and independent of resting renal oxygen consumption /
R.G. Evans // Clin Exp Pharmacol Physiol. – 2011. – Vol. 38,
N. 4. – P. 247–254.
112. Ezekowitz J. e association among renal insuciency
pharmacotherapy and outcomes in 6427 patients with heart
failure and coronary artery disease / J. Ezekowitz // J Am Coll
Cardiol. – 2004. – Vol. 44, N. 8. – P. 1587–1592.
113. Faris R.F. Diuretics for heart failure / R.F. Faris // Cohrane
Database Syst Rev. – 2012. – N. 2: CD003838.
114. Ficksen–Olsen M.J. Renal eects of angiotensin II inhibition
during increases in renal venous pressure / M.J. Ficksen–
Olsen // Hypertension. – 1992. – Vol. 19, N. 2. – P.137–141.
115. Fine L.G. Chronic hypoxia as a mechanism of progression of
chronic kidney disease: from hypothesis to novel therapeutics
/ L.G. Fine, J.T. Norman // Kidney Int. – 2008. – Vol. 74,
N. 7. – P. 867–872.
116. Fischer N.D. Renal and hormonal responses to direct renin
inhibition with aliskiren in healthy humans / N.D. Fischer //
Circulation. – 2008. – Vol. 117, N. 25. – P. 3199–3205.
117. Fogari R. New class of agents for treatment of hypertension:
focus on direct renin inhibition / R. Fogari, A. Zoppi // Vasc
Health Risk Manag. – 2010. – N. 6. – P. 869–882.
118. Forman D.E. Incidence, predictors at admission and impact
of worsening renal function among patients hospitalized with
heart failure / D.E. Forman // J Am Coll Cardiol. – 2004. –
Vol. 43, N. 1. – P. 61–67.
119. Fu W. Losartan alleviates renal brosis by down–regulating
HIF–1α and down–regulating MMP–9/TIMP–1 in rats with
215
5/6 nephrectomy / W. Fu // Ren Fail. – 2012. – Vol. 34, N. 10. –
P. 1294–1304.
120. Funakoshi H. Regulated overexpression of the A1–adenosine
receptor in mice resulted in adverse but reversible changes
in cardiac morphology and function / H. Funakoshi //
Circulation. – 2006. – Vol. 114, N. 21. – P. 2240–2250.
121. Futracul N. Microalbuminuria – a biomarker of renal
microvascular disease / N. Futracul, V. Sridama, P. Futracul
// Ren Fail. – 2009. – Vol. 31, N. 2. – P. 140–143.
122. Garibotto G. Causes of hyperhomocysteinemia in patients
with chronic kidney disease / G. Garibotto // Semin Nephrol. –
2006. – Vol. 21, N. 1. – P. 3–7.
123. Garman I.H. Omega–3 fatty acid rich diet prevents diabetic
renal disease / I.H. Garman // Am J Physiol Renal. – 2009. –
Vol. 296, N. 2. – P. F306–F316.
124. Gelasco A.K. Indoxyl sulfate induces complex redox alterations
in mesangial cells / A.K. Gelasco, J.R. Raymond // Am J Physiol
Renal. – 2006. – Vol. 290, N. 6. – P. F1515–F1558.
125. Gerling I.C. Aldosteronism: an immunostimulatory state
precedes proinammatiry / brogenic cardiac phenotype /
I.C. Gerling // Am J Physiol Heart. – 2003. – Vol. 285, N. 2. –
P. H813–H821.
126. Ghali J.K. e inuence of renal function on clinical outcome
and response to β–blockade in systolic heart failure: insight
from metoprolol CR/XL randomized intervention trial in
chronic HF / J.K. Ghali // J Cardiac Fail. – 2009. – Vol. 15,
N. 4. – P. 310–318.
127. Ghali J.K. e ecacy and safety of lixivaptan in outpatients
with heart failure and volume overload : results of multicenter,
randomized, double–blind, placebo–controlled, parallel–
group study / J.K. Ghali, C. Orlandi, W.T. Abraham // Eur J
Heart Fail. – 2012. – Vol. 14, N. 6. – P. 642–651.
128. Gheorghiade M. Pathophysiological targets in the early phase
of acute failure syndromes / M. Gheorghiade // Am J Cardiol. –
2005. – Vol. 96, N. 6 [Suppl 1]. – P. 11–17.
216
129. GISSI–HF Investigators. Eect of n–3 polyunsaturated fatty
acids in patients with chronic heart failure (the GISSI–HF
trial): a randomized, double–blind, placebo–controlled trial
// Lancet. – 2008. – Vol. 372, N. 9645. – P. 1223–1230.
130. Go A.S. Chronic kidney disease and risk of death,
cardiovascular events and hospitalization / A.S. Go // N Engl
J Med. – 2004. – Vol. 351, N. 13. – P. 1299–1305.
131. Go A.S. Hemoglobin level, chronic kidney disease and risk of
death and hospitalization in adults with chronic heart failure:
Anemia in Chronic Heart Failure: Outcomes and Recourse
Utilization (ANCHOR) Study // Circulation. – 2006. –
Vol. 113, N. 23. – P. 2713–2723.
132. Goland S. Appropriateness and complications of the use of
the spironolactone in patients treated in heart failure clinic
/ S. Goland // Eur J Intern Med. – 2011. – Vol. 22, N. 4. –
P. 424–427.
133. Gottlieb S.S. e prognostic importance of dierent denitions
of worsening renal function in congestive heart failure / S.S.
Gottlieb // J. Card Fail. – 2002. – Vol. 8, N. 3. – P. 136–141.
134. Grassi G. Early sympatic activation in the initial stages of
chronic renal disease / G. Grassi // Hypertension. – 2011. –
Vol. 57, N. 4. – P. 846–851.
135. Greither A. Pharmacokinetics of furosemide inpatients with
congestive heart failure / A. Greither, S. Goldman, J.S. Edelen
// Pharmacology. – 1979. – Vol. 19, N. 1. – P. 121–131.
136. Groenveld H.F. Anemia and mortality in heart failure
patients. A systematic review and meta–analysis /
H. F. Groenveld // J Am Coll Cardiol. – 2008. – Vol. 52, N. 10. –
P. 818–827.
137. Guglin M. Renal dysfunction in heart failure is due to
congestion but not low output / M. Guglin, A. Rivero,
M. Garcia // Clin Cardiol. – 2011. – Vol. 34, N. 2. – P. 113–116.
138. Hamaguchi S. Chronic kidney disease as an independent
risk factor for long–term adheres outcomes in patients
hospitalized with heart failure in Japan / S. Hamaguchi //
Circ J. – 2009. – Vol. 73, N. 8. – P. 1442–1447.
217
139. Harada K. Benecial eects of torasemide on systolic wall
stress and sympathetic nervous activity in asymptomatic or
mildly symptomatic patients with heart failure / K. Harada
// J Cardiovasc Pharmacol. – 2009. – Vol. 53, N. 6. – P. 468–473.
140. He M. Inhibition of renin/prorenin receptor attenuated
mesangial cell proliferation and reduces associated brotic
factor release / M. He // Eur J Pharmacol. – 2009. – Vol. 606,
N. 1–3. – P. 155–161.
141. Heinz J. Homocysteine as a risk factor for cardiovascular
disease in patients treated with dialysis: a meta–analysis /
J. Heinz // Am J Kidney Dis. – 2009. – Vol. 54, N. 3. – P. 478–489.
142. Hering D. Tonic hemoreex activation contributes to the
elevated muscle sympathetic nerve activity in patients with
chronic renal failure / D. Hering // J Hypertens. – 2007. –
Vol. 25, N. 1. – P. 157–161.
143. Higgins D.F. Hypoxia promotes brogenesis in vivo via HIF–1
stimulation of epithelial– to–mesenchymal transition /
D.F. Higgins // J Clin Invest. – 2007. – Vol. 117, N. 2. –
P. 3810–3820.
144. Hirose T. Gene expression of (pro)renin receptor is
upregulated in hearts and kidneys of rats with congestive
heart failure / T. Hirose // Peptide. – 2009. – Vol. 30, N. 12. –
P. 2316–2322.
145. Hirose T. Increased expression of (pro)renin receptor in the
remnant kidney of 5/6 nephrectomized rats / T. Hirose //
Regul Pept. – 2010. – Vol. 159, N. 1–3. – P. 93–99.
146. Hisatake S. Comparative analysis of the therapeutic eects
of long–acting and short–acting diuretics in the treatment
of chronic heart failure using
(123)
I–metaiodobenzylguanide /
S. Hisatake // Eur J Heart Fail. – 2011. – Vol. 13, N. 8. –
P. 892 – 898.
147. Ho J. C. Omacor, n–3 polyunsaturated fatty acids, attenuated
albuminuria and renal dysfunction with decrease of SREBP–1
expression and triglyceride amount in the kidney of type–II
diabetic animals / J. C. Ho // Nephron Dial Transplant. –
2010. – Vol. 25, N. 5. – P. 1450–1457.
218
148. Ho J. E. Relation of improvement in estimated glomerular
ltration rate with atorvastatin to reductions in
hospitalizations for heart failure (from the Treating to New
Targets [TNT] Study / J.E. Ho // Am J Cardiol. – 2012. – Vol.
109, N. 12. – P. 1761–1766.
149. Hong W. Dierential eects of arginine methylation on
diastolic dysfunction and disease progression in patients
with systolic heart failure / W. Hong // Eur Heart J. – 2008. –
Vol. 29, N. 20. – P. 2505–2513.
150. Hsu C.P. Asymmetric dimethylarginine predicts clinical
outcomes in ischemic chronic heart failure / C.P. Hsu,
S.J. Lin, M.Y. Chung // Atherosclerosis. – 2012. – Vol. 225,
N. 2. – P. 204–210.
151. Huang J. Renal (pro)renin receptor contributes to development
of diabetic kidney disease through transforming growth
factor–β1–connective tissue growth factor signaling cascade
/ J. Huang, L.C. Matavelli, H.M. Siragy // Clin Exp Pharmacol
Physiol. – 2011. – Vol. 38, N. 4. – P. 215–221.
152. Huang Y. Renin increases mesangial cell transforming growth
factor–β1 and matrix proteins through receptor–mediated,
angiotensin II–independent mechanisms / Y. Huang //
Kidney Int. – 2006. – Vol. 69, N. 1. – P. 105–113.
153. Huang Y. Renin–stimulated TGF–β1 expression is regulated
by a mitogen–activated protein kinase in mesangial cells /
Y. Huang // Kidney Int. – 2007. – Vol. 72, N. 1. – P. 45–52.
154. Huskey J. Eect of simvastatin on kidney function loss
in patients with coronary heart disease: ndings from
Scandinavian Simvastatin Survival Study (4S) / J. Huskey ] //
Atherosclerosis. – 2009. – Vol. 2005, N. 1. – P. 202–206.
155. Jackson C.E. Albuminuria in chronic heart failure: prevalence
and prognostic importance / C.E. Jackson // Lancet. – 2009. –
Vol. 374, N. 9689. – P. 543–550.
156. Jump D.B. e biochemistry of n–3 polyunsaturated fatty
acids // J Biol Chem. – 2002. – Vol. 277, N. 11. – P. 8755–8758.
219
157. Ichihara A. Contribution of non–proteolytically activated
prorenin in glomeruli of hypertensive renal damage /
A. Ichihara // J Am Soc Nephrol. – 2006. – Vol. 17, N. 9. –
P. 2495–2503.
158. Ichihara A. e (pro)renin receptor and the kidney / A. Ichihara
// Semin Nephrol. – 2007. – Vol. 27, N. 25. – P. 524–528.
159. Inoue B.H. Increased of abundance and transport activity in
renal proximal tubule of rats with heart failure / B.H. Inoue //
Am J Physiol Regul. – 2012. – Vol. 302, N. 1. – P. R166–R174.
160. Inker L.A. Estimation glomerular ltration rate using
the chronic kidney disease–epidemiology collaboration
creatinine equation: better risk predictions / Inker L.A.,
K.Sha, A.S. Levey // Circ Heart Fail. – 2012. – Vol. 5,
N. 3. – P. 303–306.
161. Ito H. Dierential eects of carvedilol and metoprolol on
renal function in patients with heart failure / H. Ito // Circ
J. – 2010. – Vol. 74, N. 8. – P. 1578–1583.
162. Kalaitzidis R.G. e role of statins in chronic kidney disease
/ R.G. Kalaitzidis, M.S. Elisaf // Am J Nephrol. – 2011. –
Vol. 34, N. 1. – P. 195–202.
163. Kaneshiro Y. Slowly progressive, angiotensin II–independent
glomerulosclerosis in human (pro)renin receptor–transgenic
rats / Y. Kaneshiro // J Am Soc Nephrol. – 2007. – Vol. 18,
N. 6. – P. 1789–1795.
164. Kang H.K. Urinary N–acetyl–beta–D–glucosaminidase and
malonadialdehyde as a markers of renal damage in burned
patients / H.K. Kang // J Korean Med Sci. – 2001. – Vol. 16,
N. 5. – P. 598–602.
165. Karolczak K. Mechanism of action of homocysteine and its
thiolactone in hemostasis system / K. Karolczak, B. Olas //
Physiol Res. – 2009. – Vol. 58, N. 5. – P. 623–633.
166. Kestenbaum B.R. Incidence and progression of coronary
calcication in chronic kidney disease. e Multi–Ethnic
Study of atherosclerosis / B.R. Kestenbaum // Kidney Int. –
2009. – Vol. 76, N. 9. – P. 991–998.
220
Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]